omega3 in depression

Comparison of the efficacy of omega-3 as an adjunctive therapy of sertraline and venlafaxine in improving symptoms of major depressive disorder : A Double-blind , placebo controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190302042885N1

Enrollment

Registered

2020-04-20

Start date

2019-03-21

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depression. Depression NOSDepressive disorder NOS

Interventions

Intervention 1: Intervention group: 50 mg Sertraline daily plus two grams of Omega 3 daily. Intervention 2: Intervention group: 75 mg of venlafaxine daily plus two grams of omega 3 daily. Intervention

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Having DSM-V diagnostic criteria for major depressive disorder with clinical diagnosis of psychiatrist Earning a score higher than 7 based on Hamilton's Questionnaire (HAM-D) Obtain informed consent from the patient Age between 18 and 60 years There is no psycho-manifestation

Exclusion criteria

Exclusion criteria: Drug abuse and drug abuse other than nicotine and caffeine IQ less than 70 There is another psychiatric disorder in the diagnostic axis one The presence of a medical condition (especially liver disease, cardiovascular disease and hypertension) or significant neurology

Design outcomes

Primary

Measure	Time frame
Hamilton questionnaire score. Timepoint: Before treatment and 4 weeks after treatment. Method of measurement: Hamilton questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Ahadi Fard Moghadam

Alborz Univesity of Medical Science

mohammadafm72@gmail.com+98 26 3677 3900

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026